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PREVENTION OF KNEE OSTEOARTHRITIS IN OVERWEIGHT FEMALES;
THE FIRST PREVENTIVE RANDOMIZED CONTROLLED TRIAL
J. Runhaar 1, M. van Middelkoop 1, D. Vroegindeweij 2, E.H. Oei 1,
M. Reijman 1, G.J. van Osch 1, B.W. Koes 1, S.M. Bierma-
Zeinstra 1. 1 Erasmus MC, Rotterdam, Netherlands; 2Maasstad Hosp.,
Rotterdam, Netherlands
Purpose: With increasing rates of obesity, continued aging of the
population and a lack of available disease modifying interventions for
osteoarthritis (OA), primary prevention of OA is of great signiﬁcance.
Obesity is known to be one of few modiﬁable risk factors for incident
knee OA. The purpose of the present study was to evaluate the effect of
a pragmatic tailor made weight reduction program and of oral glucos-
amine sulphate (double blind; placebo-controlled), in a factorial design,
on the incidence of knee OA over 2.5 years of follow-up in overweight,
middle-aged females; free of clinical and radiological knee OA at
baseline (ISRCTN 42823086). Worldwide, this is the ﬁrst large RCT on
prevention of knee OA. Here we present the effects of the weight
reduction program.
Methods: 50 general practitioners in the area of Rotterdam, the
Netherlands, contacted all women between 50 and 60 years registered
at their practice (6691 women). All women with a self reported BMI 
27 interested to participate in the study (889 women) were screened on
the inclusion criteria. Subjects had to be free of knee OA according to the
ACR criteria, free of contraindications to MRI, free of rheumatic diseases
and not using oral glucosamine during the past 6 months. In total, 407
women met all inclusion criteria, were invited for baseline measure-
ments and were randomized. Based on baseline standardized semi-
ﬂexed X-rays, all knees with a K&L-grade of  2 were excluded. Half of
all women were randomized into the control group (CG) and received
no intervention onweight reduction. The other half was assigned to the
weight reduction group (WRG) and was referred to a local dietician for
guidance on nutrition and physical activity behaviours based on Moti-
vational Interviewing. In addition, they were invited to join a physical
activity class of 20 weekly group lessons, guided by a physical therapist.
Every 6 months, all 407 subjects received a home visit to measure body
weight, replace study medication and check their well-being. Pre-
speciﬁed primary outcome measure was incidence of knee OA, deﬁned
by incidence of either K&L-grade 2, joint space narrowing of 1.0mm
or clinical knee OA according to the ACR criteria.
Results: At baseline, subjects were 55.7  3.2 years old, had a mean
body weight of 88.7  13.2 kg and a mean BMI of 32.4  4.3 kg/m2;
Ăequally spread over both groups. All 2.5 year follow-up measurements
have been completed (10% lost to follow-up). Almost 75% of WRG
attended the physical activity class at least once (0 to 21 lessons; 7 on
average). Ninety percent visited the dietician at least once (0 to 32
visits; 6 on average). After 2.5 years and on all intermediary measure-
ments, body weight was not signiﬁcantly different between WRG and
CG. However at 6 months follow-up (during highest intensity of the
interventions), WRG had a signiﬁcantly larger reduction in body weight
than CG (-0.9 kg in WRG vs +0.9 kg in CG, p < 0.00), and a signiﬁcant
larger part of WRG (12%) fulﬁlled the pre-speciﬁed objective of 5 kg or
5% weight reduction than in CG (6%, p ¼ 0.04). After 2.5 years, subjects
compliant to the weight reduction intervention (6 visits and 7
lessons) showed a meanweight reduction of 1.4  5.5 kg, compared 0.1
 6.3 kg in the controls (p ¼ 0.22). Up to now, only 50% of the primary
outcome measure has been scored. Based on these data, in the present
population incidence of knee OA was 19%. To avoid publication of
unfounded study results, no interim analyses on the primary outcome
measure were performed. All primary outcomes will be available in
February 2012 and will be presented at the Congress.
Conclusions: The pragmatic tailor made intervention did not show
effects on body weight throughout the 2.5 years follow-up, but several
measures of weight reduction showed a signiﬁcant effect in favour of
WRG within the ﬁrst 6 months. Sample size calculations were based on
a 20% incidence in the control group, 10% incidence in the intervention
group and 20% lost to follow-up. So far, incidence number reached
expected levels and percentage lost to follow-up was considerably
lower than expected. Final results will be available at the OARSI World
Congress.
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CARTILAGE LOSS DURING SYMPTOMATIC MAINTENANCE AFTER
A CLINICALLY SIGNIFICANT WEIGHT LOSS IN OBESE
OSTEOARTHRITIS PATIENTS: A RANDOMIZED CONTROLLED TRIAL
M. Henriksen 1, R. Christensen 1,2, D.J. Hunter 3, E. Dam4,
S. Lohmander 2,5, M. Boesen 1,6, H. Gudbergsen 1, H. Bliddal 1. 1 The
Parker Inst., Copenhagen, Denmark; 2Univ. of Southern Denmark,
Odense, Denmark; 3Univ. of Sydney, Sydney, Australia; 4Biomediq,
Copenhagen, Denmark; 5Univ. of Lund, Lund, Sweden; 6Dept. of
Radiology, Frederiksberg Hosp., Copenhagen, Denmark
Purpose: Weight loss in overweight patients with knee osteoarthritis
(OA) is recommended because it effectively induces symptomatic relief.
However, maintaining weight loss and symptomatic relief is a chal-
lenge, and the effects of weight and symptom maintenance programs
on cartilage deterioration are unknown. The purpose of this study was
to compare cartilage loss in the knee joint over 1-year of dietary
consultancy or therapeutic exercise vs. control in obese knee OA
patients after a clinically signiﬁcant weight loss.
Methods: Obese individuals (>50 years) with knee OA (ACR criteria),
and motivated for weight loss, were enrolled in a 16-week weight loss
program that induced a clinically signiﬁcant weight loss (>10%). They
were then randomized to either 1-year maintenance program with [D]
continuous dietary consultations, or [E] knee exercise program super-
vised by a physical therapist or [C] a control group receiving no support
from the study team for 1 year. The primary endpoint was annual
change in total knee joint cartilage volume assessed by MRI. Secondary
outcomes included changes in the individual regional cartilage volumes
assessed by automatic segmentation of MRI and changes in average
knee symptoms measured as the mean of 4 out of the 5 KOOS subscales
(excluding sports and recreation subscale) over 1 year. The outcomes
were analyzed statistically using ANCOVAwith a factor for maintenance
group, adjusting for the level at baseline.
Results: 192 participants, mean age 63 years (SD 6), mean weight 103.2
kg (15.0), and BMI of 37.3 (4.8) were randomized (1:1:1; 64 patients in
each group). The average annual loss in total cartilage volume across
groups was 1,150 mm3. There were no statistically signiﬁcant group
differences in changes in cartilage volumes at the 1 year follow-up
(Table). The average symptoms deteriorated by 8.4 points (SE 1.1) across
groups. There were also no statistically signiﬁcant group differences for
the average symptoms (KOOS) or any of the other secondary outcomes.
Ancillary analysis showed that the annual changes in total cartilage
volume were not associated with annual changes in average symptoms
(r¼-0.007, P¼0.93).
Conclusion: This study showed no differences in knee joint cartilage
loss between obese knee OA patients who after a signiﬁcant weight loss
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group for 1 year. The cartilage loss was not associated with changes in
symptoms.Trial registration: {NCT00655941}ANCOVA results for changes in weight, BMI and cartilage volumes (mm3) and average symptoms (KOOS)
Group C Group D Group E ANCOVA
Mean 95% CI Mean 95% CI Mean 95% CI P-value
Weight, kg -9.8 -11.7 to -7.8 -12.8 -14.7 to -11.0 -8.0 -9.9 to -6.1 0.0018
BMI -3.5 -4.2 to -2.8 -4.6 -5.3 to -4.0 -2.9 -3.6 to -2.2 0.0023
Cartilage Volume (mm3)
Total knee -1219 -1378 to -1061 -1119 -1273 to -965 -1112 -1275 to -949 0.5770
Lateral Femoral -251 -284 to -219 -227 -259 to -196 -236 -270 to -203 0.5755
Medial Femoral -319 -363 to -275 -269 -311 to -226 -285 -330 to -340 0.2651
Patellar -214 -261 to -167 -202 -247 to -156 -167 -215 to -119 0.3595
Lateral Tibial -265 -331 to -199 -246 -309 to -182 -279 -347 to -211 0.7745
Medial Tibial -172 -238 to -107 -173 -237 to -110 -146 -214 to 78 0.8099
Average Symptoms (KOOS) 8.3 4.6 to 11.9 9.0 5.5 to 12.6 7.8 4.1 to 11.4 0.884340
BLOCKING COLLAGENOLYSIS PREVENTS AGGRECAN LOSS MORE
EFFECTIVELY THAN BLOCKING AGGRECANOLYSIS IN THE
AGGRECAN INTERGLOBULAR DOMAIN, IN VITRO AND IN VIVO
S.J. Gauci 1, C.B. Little 2, A.J. Fosang 3. 1Murdoch Childrens Res. Inst., VIC,
Australia; 2Raymond Purves Bone & Joint Res. Labs, Univ. of Sydney,
NSW, Australia; 3Univ. of Melbourne & Murdoch Childrens Res. Inst.,
VIC, Australia
Purpose: We have compared knockin mice with aggrecan and type II
collagenresistant toaggrecanases, collagenases,orboth familiesofenzymes,
to identify the most important proteolytic driver for cartilage erosion.
Speciﬁcally, the cleavage site in the aggrecan interglobular domain (IGD) of
Jaffa is changed from E373Y374ALG to E373Y374NVY and the collagenase
cleavage site in the a1(II) chain of Bailey is changed from PQG775Y776LAG to
PPG775Y776MPG.The Jaffamutationdoesnot inﬂuenceaggrecanasecleavage
at sites in the chondroitin sulphate-rich region of aggrecan. In contrast,
blocking cleavage at the primary collagenase cleavage site prevents
secondaryand subsequent cleavage events inBailey type II collagen. Juniper
mice are resistant to both aggrecanases and collagenases
Methods: Aggrecan released into the medium from Wildtype, Bailey,
Jaffa and Juniper femoral head cartilage explants (n¼ 5-6 per genotype),
treated for 3 days  IL-1, was measured by the DMMB assay. Cartilage
used in the explant experiments was homozygous for all genotypes. We
used the DMM surgical model of OA to compare tibial cartilage erosion
in Wildtype, Bailey, Jaffa and Juniper mice at 8-weeks post-surgery.
Morphological joint abnormalities in homozygous Bailey precluded
their use in arthritis studies. Accordingly, the in vivo comparisons were
made between heterozygous Bailey, homozygous Jaffa and Juniper mice
that were heterozygous for the Baileymutation and homozygous for the
Jaffa mutation. Sagittal sections collected at 40mm intervals through the
medial compartment of the knee were scored for aggrecan loss and
cartilage erosion by two independent scorers blinded to the genotype.
The data were analysed by the Mann-Whitney U-test
Results: Aggrecan loss from explants treated with IL-1a was signiﬁ-
cantly reduced in all mutant genotypes compared with Wildtype.
Juniper explants lost the least amount of aggrecan. The hierarchy of
aggrecan loss was Wildtype > Jaffa > Bailey > Juniper samples.
Aggrecan loss from explants treated with retinoic acid was also signif-
icantly reduced in all mutant genotypes compared with wildtype; again
Juniper explants lost the least amount of aggrecan. However, withretinoic acid treatment, the hierarchy of aggrecan loss was Wildtype >
Bailey > Jaffa > Juniper samples. We measured aggrecan loss and
cartilage erosion 8-weeks after DMM surgery and as predicted, found
that both aggrecan loss and tibial cartilage erosion were signiﬁcantly
reduced in Juniper comparedwithWildtype. For aggrecan loss, whereas
there was no protection in Jaffa compared with Wildtype at 8 weeks,
the aggrecan loss from Bailey was signiﬁcantly less than for Wildtype.
For cartilage erosion, both Bailey and Jaffa were protected compared
with Wildtype at 8 weeks. Similarly, Juniper was better protected
against cartilage erosion than either Jaffa or Bailey
Conclusions: Mutations that partially block collagenolysis (heterozy-
gous Bailey) and aggrecanolysis (homozygous Jaffa for the IGD site only)
protect against cartilage erosion in experimental OA. Furthermore,
protecting collagen II against collagenase attack is equal to, or better
than, protecting aggrecan against IGD aggrecanase cleavage, in terms of
cartilage erosion and aggrecan loss respectively (see Figure)41
S100A8 AND S100A9 ACT AS ‘PRIMERS’ OF A CATABOLIC RESPONSE
IN CHONDROCYTES BUT ADDITIONAL SIGNALS ARE REQUIRED TO
ACTIVATE CARTILAGE DEGRADATION
A. van Hummel 1,2, C. Little 2, T. Vogl 3, J. Roth 3, H. Zreiqat 1. 1 Tissue
Engineering and Biomaterials Unit, Faculty of Engineering, The Univ. of
Sydney, Sydney, Australia; 2Raymond Purves Bone & Joint Res. Lab., The
Kolling Inst. Of Med. Res., Univ. of Sydney, Royal North Shore Hosp.,
Sydney, Australia; 3 Inst. of Immunology, Univ. of Muenster, Muenster,
Germany
Purpose: Calcium binding proteins S100A8 and S100A9 are increased in
cartilage in acute and chronic inﬂammatory arthritis; however their
role in osteoarthritis (OA) is less clear. Chondrocyte S100A8 and S100A9
mRNA are increased during the onset of surgically induced murine OA,
but both are signiﬁcantly downregulated as OA progresses. Interest-
ingly, recent studies have shown that cartilage in S100A9-/- deﬁcient
mice is protected from degradation in joint instability accompanied by
signiﬁcant synovitis (collagenase-induced-) but not surgically-induced-
OA. Whether this is due tomore persistent expression of S100A8 and/or
A9 or release of additional co-factors from the inﬂamed synovium in the
collagenase model is unclear. S100A8 and S100A9, but not the hetero-
dimer (S100A8/A9) rapidly induceMMP and ADAMTSmRNA expression
in chondrocytes, but whether this leads to actual cartilage matrix
breakdown has not been resolved. The aim of this study was to deter-
mine whether S100A8 or S100A9 alone or in combination with IL-1 can
activate MMPs and aggrecanases with resultant chondrolysis and
whether this is time-dependent.
Methods: Normal ovine articular cartilage explants were cultured for 1,
2, 4, 7 or 14 days in serum-free media  10-7M human S100A8, S100A9
or S100A8/A9, with or without 10ng/ml IL-1a (n¼6/treatment). Gene
expression of S100A8, S100A9, key cartilage proteins, metal-
loproteinases and their inhibitors was measured using qRT-PCR.
Collagen and aggrecan release were measured as hydroxyproline and
glycosaminoglycan respectively. Media MMP-2 and MMP-9 activity
were evaluated by gelatin zymography and MMP-13 using a ﬂuoro-
metric assay.
Results: S100A8 and S100A9 alone signiﬁcantly (p<0.05) up-regulated
MMP1, MMP3, S100A9, ADAMTS5 and MMP13 mRNA throughout the
